Other

Chugai Seiyaku Kabushiki Kaisha

Japan Science and Technology Agency

Otsuka Pharmaceutical Company, Limited

Akira Tsuji

Jun-Ichi Nezu

Asuka Ose

Ikumi Tamai

Yoshimichi Sai

Hidekazu Toyobuku

Masaaki Odomi

Toru Oya

Ken-ichi Miyamoto

Noubuhiko Yui

The present invention provides a pharmaceutical preparation that can improve absorption of a pharmaceutical compound in the gastrointestinal tract and that provides, through oral administration or like method, a blood concentration from which sufficient remedial effects can be expected, and a method for producing such a preparation. The invention is directed to a pharmaceutical preparation exhibiting excellent gastrointestinal absorbability comprising a compound recognized by a proton-coupled transporter and a pH-sensitive polymer in an amount sufficient for the gastrointestinal tract to acquire a pH at which the proton-coupled transporter optimally absorbs the compound into a cell.

Gastrointestinal absorption enhancer mediated by proton-coupled transporter and its preparing method

Four novel transporter genes were successfully cloned by screening novel transporter genes based on the human OATP transporter gene sequence. These transporters are useful in the development of drugs by taking advantage of the activity of transporting biological substances and various drugs. It was also found that these transporter genes have single nucleotide polymorphisms (SNP). Gene diagnosis based on the polymorphisms (such as SNP) in these transporter genes enables one to judge, for example, the efficacy of a drug therapy.

Transporter genes OATP-B, C, D, and E

The present invention is to provide a tissue-specific transporter inhibitor which is not absorbed through the digestive tract and can prevent deterioration in the QOL of a patient caused by diet therapy, and a therapeutic drug for tissue dysfunction diseases and a therapeutic drug for suppressing the progress of chronic renal failure containing the inhibitor as an active ingredient. A tissue-specific transporter inhibitor which is not absorbed through the digestive tract is constructed by introducing a dipeptide which is a ligand of an oligopeptide transporter 1 into a supramolecular structure polyrotaxane wherein its structurally modified active residue is expected to be excellent in the interaction with a transmembrane transporter.

Tissue-specific transporter inhibitor

Transporter genes OATP-B,C,D, and E

Growing community of inventors

Kanazawa, Japan

Akira Tsuji